G-BA added benefit determinations shape reimbursement and market access outcomes for orphan therapies in Germany, yet a large proportion of assessments result in a non-quantifiable rating. This analysis, drawing on 198 G-BA assessments across 128 orphan products evaluated through GPI’s Horizon framework, examines how trial design characteristics relate to added-benefit outcomes. The findings show a consistent pattern: clinical uncertainty, driven by structural limitations in the evidence base, is the primary mechanism connecting trial design to HTA outcome.
What determines G-BA added benefit outcomes for orphan drugs in Germany?
Background
Demonstrating value for orphan therapies remains one of the most complex challenges in health technology assessment. In Germany, the added-benefit determination conducted by the Gemeinsamer Bundesausschuss (G-BA) plays a central role in shaping reimbursement and market access outcomes. However, for many rare disease therapies, evidence generation is constrained by small patient populations, making it difficult to produce the level of comparative clinical evidence typically expected in HTA evaluations.
Within the German orphan drug framework, an added benefit is legally presumed upon regulatory approval. However, when the available evidence does not allow the magnitude of benefit to be clearly quantified, the G-BA frequently assigns a “non-quantifiable added benefit” rating. As a result, a substantial proportion of orphan drug assessments fall into this category, often reflecting limitations in the available clinical evidence rather than the absence of therapeutic value.
How does trial design quality relate to G-BA added benefit ratings?
Methodology
Using our GPI Horizon value framework, which evaluates therapies across domains such as disease burden, product characteristics, trial design, and clinical efficacy, we analysed 128 orphan products representing 198 G-BA assessments in Germany. The framework provides a structured way to assess how different evidence characteristics contribute to the overall value profile of a therapy and how these characteristics align with HTA outcomes. In this analysis, we focused on the trial design domain to explore how evidence structure relates to added-benefit outcomes.
Evidence Patterns Across G-BA Benefit Levels
Across orphan therapies assessed by the G-BA, both overall value scores and trial design scores decline progressively as the level of added benefit decreases. Products achieving a major added benefit demonstrate the strongest trial design characteristics and highest overall value scores, while therapies where added benefit is not proven consistently show the weakest evidence profiles.
This pattern highlights the central role of robust comparative evidence in supporting favourable HTA outcomes in Germany (Figure 1).
Figure 1 illustrates the relationship between HTA benefit levels and scores from the trial design domain of GPI Horizon.
(Median overall value and trial design scores across orphan products in the GPI Horizon database were analysed).
Figure 2 further illustrates the distribution of evidence maturity across benefit categories, highlighting the predominance of Phase III evidence in higher benefit levels and the mixed evidence profile among therapies receiving non-quantifiable benefit.
Why does clinical uncertainty affect whether added benefit can be quantified?
Clinical Uncertainty: The Mechanism Connecting Trial Design to Outcome
Clinical uncertainty appears to be the key mechanism linking trial design to HTA outcomes in Germany. While Phase III evidence dominates therapies achieving major, considerable, and minor added benefit, the presence of late-phase trials alone does not guarantee that benefit can be quantified. Instead, the decisive factor often lies in the interpretability of the evidence. Randomised comparative trials with appropriate endpoints allow the magnitude of treatment effect to be assessed with greater confidence, whereas single-arm designs, small patient populations, or uncertain endpoints introduce substantial uncertainty. In such cases, even promising therapies may receive non-quantifiable benefit ratings because the available evidence does not allow the magnitude of benefit relative to standard of care to be reliably determined.
Products achieving major or considerable added benefit are typically supported by randomised comparative trials, clearly defined endpoints, and evidence packages where treatment effects can be interpreted with relatively low uncertainty.
In contrast, therapies receiving non-quantifiable benefit or where added benefit is not proven frequently exhibit structural evidence limitations that translate into higher levels of uncertainty during assessment. These include reliance on single-arm trials, absence of direct comparators, small patient populations, or challenges in interpreting surrogate endpoints. Within the GPI Horizon framework, these characteristics are captured through lower scores in the trial design and clinical evidence domains, reflecting the greater uncertainty surrounding the observed treatment effect.
Interestingly, products achieving minor added benefit often occupy an intermediate position. In these cases, comparative evidence is available but residual uncertainty remains regarding the magnitude, durability, or generalisability of the treatment effect.
Our review of G-BA assessment reports using GPI Horizon framework shows that clinical uncertainty often arises from recurring structural limitations in the evidence base. Several themes appear consistently across orphan drug evaluations. These include reliance on single-arm or non-comparative study designs, which limit the ability to estimate treatment effects relative to standard of care; small patient populations, which lead to wide confidence intervals and reduced statistical robustness; and immature or incomplete datasets, where limited follow-up restricts the assessment of long-term outcomes or durability of response.
Another frequently cited challenge relates to the choice and interpretation of endpoints. In a number of assessments, improvements were observed in surrogate or intermediate outcomes that were not considered patient-relevant, or where statistically significant differences in mortality, morbidity, or quality of life were not demonstrated. In other cases, variability in response rates or heterogeneous patient populations introduced additional uncertainty regarding the magnitude and generalisability of treatment effects.
Taken together, these critiques illustrate how structural characteristics of clinical trials translate into higher levels of uncertainty during HTA evaluation. Within the framework analysis, therapies associated with stronger trial design characteristics and clearer evidence on patient-relevant outcomes tend to achieve higher added-benefit ratings. Conversely, evidence packages affected by the limitations described above often result in benefit determinations where the magnitude of added benefit cannot be confidently quantified.
See how GPI Horizon scores your rare disease asset against G-BA evidence criteria.
Horizon evaluates your therapy’s trial design characteristics, endpoint quality, and evidence maturity against the same domains that shape G-BA added-benefit outcomes, giving your team a structured view of HTA risk before you commit to a development strategy.
What do these findings mean for rare disease evidence generation strategy?
Conclusion
Our analysis highlights how the structure and interpretability of clinical evidence can shape HTA outcomes for orphan therapies in Germany. The findings suggest that the ability to clearly demonstrate the magnitude of therapeutic benefit, rather than simply the presence of clinical evidence, often determines whether added benefit can be confidently quantified. As rare disease pipelines continue to expand, frameworks such as GPI Horizon can help systematically assess evidence characteristics and identify potential risks of uncertainty early in development. Early consideration of trial design, endpoint selection, and comparative evidence strategy may therefore play a critical role in shaping HTA outcomes and more successful market access strategies.
FAQs
A: Non-quantifiable added benefit is a rating assigned by Germany’s G-BA when the available evidence is sufficient to presume a therapy has added benefit (as required under the orphan drug framework) but does not allow the magnitude of that benefit to be clearly determined. It typically arises when evidence limitations such as single-arm trial designs, small patient populations, or uncertainty around surrogate endpoints prevent a reliable quantification of the treatment effect relative to standard of care.
A: GPI’s analysis of 198 G-BA assessments shows a clear relationship between trial design quality and added-benefit outcomes. Products achieving major or considerable added benefit are typically supported by randomised comparative trials with clearly defined, patient-relevant endpoints. Those receiving non-quantifiable ratings or where added benefit is not proven tend to have structural evidence limitations including single-arm designs, small populations, or immature datasets. The GPI Horizon framework captures these characteristics through scores in the trial design and clinical evidence domains.
A: The analysis suggests that early consideration of trial design, endpoint selection, and comparative evidence strategy can materially shape HTA outcomes. While rare disease trials face real constraints around patient population size, understanding how specific evidence characteristics map to G-BA benefit categories before committing to a study design allows teams to identify and address potential uncertainty risks earlier in development. Structured analytical frameworks such as GPI Horizon can support this type of pre-launch evidence assessment.
Planning evidence generation for a rare disease asset targeting Germany?
GPI’s Horizon framework gives development and market access teams a systematic way to assess how evidence characteristics align with G-BA evaluation criteria, identifying potential uncertainty risks at the pre-launch stage.
